Cotreatment of camrelizumab, anti-PD-1 mAb, and revoceranib, VEGFR-2 tyrosine kinase inhibitor, for unresectable HCC patients demonstrated increased PFS and OS compared to sorafenib as a first-line therapy [27]. Here, PDCD1 is linked to hepatocellular carcinoma.